NCT06306638

✓ Unanimous Initial: inpatient Requery: outpatient — The study describes interventions such as photodynamic therapy and palliative radiotherapy which are typically delivered on an outpatient basis, and there is no mention of patients being admitted or hospitalized for the duration of the treatment.

✓ Unanimous Initial: inpatient Requery: outpatient — The study involves bronchoscopic procedures, radiation therapy sessions, and photodynamic therapy treatments that are typically performed as outpatient procedures where patients receive treatment and then go home.

✓ Unanimous Initial: outpatient Requery: outpatient — The trial involves bronchoscopic procedures and palliative radiotherapy with follow-up visits at specific intervals, indicating patients return home after treatments rather than being continuously hospitalized.

✓ Unanimous Initial: no Requery: no — The intervention is testing interstitial photodynamic therapy following palliative radiotherapy, not a palliative care service or consultation.

✓ Unanimous Initial: yes Requery: no — The intervention being tested is interstitial photodynamic therapy (I-PDT) with endobronchial ultrasound following radiotherapy - palliative radiotherapy is used as a standard component but the experimental intervention is the photodynamic therapy technique, not palliative care itself.

✓ Unanimous Initial: no

✓ Unanimous Initial: other Requery: other — Visudyne, a photosensitizer used in photodynamic therapy, is a pharmacologic intervention that does not fit in the specified categories such as controlled substances, chemotherapy, or immunotherapy. Thinking: off label use — Verteporfin is an FDA-approved photosensitizer for macular degeneration but is being used here for airway tumor treatment, a non-approved indication.

✓ Unanimous Initial: other Requery: other — The study uses verteporfin (visudyne), a photosensitizer drug that is FDA-approved but represents a specialized pharmacologic intervention for photodynamic therapy rather than fitting into the specific categories like controlled substances, chemotherapy, or immunotherapy. Thinking: off label use — Verteporfin (Visudyne) is FDA-approved for macular degeneration but is being used here for cancer treatment via photodynamic therapy.

✓ Unanimous Initial: not yet FDA/EMA approved Requery: not yet FDA/EMA approved — Verteporfin is being used as an investigational photosensitizer in combination with interstitial photodynamic therapy for malignant central airway obstruction, which is an experimental application.